Latest Bite Stories

ORLANDO, Fla., April 5, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer. The data were presented in a late-breaking oral presentation at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando. PVS-30200, which utilizes...

REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations. This study was published in the March 1, 2011 issue...

Therapik® provides bug bite relief and bug bite treatment, in a new, mess-free, drug-free and eco-friendly way. Fort Lauderdale, FL (PRWEB) February 2, 2011 The FDA confirmed the following: Therapik® is indicated for use to provide temporary bug bite relief, from the pain and itching resulting from insect stings and bites from bees, wasps and mosquitoes, by increasing localized blood flow. Eco-friendly, as well as drug-free and mess-free, Therapik® uses directed heat to...

Dogs attack face and eyesAs dog bites become an increasingly major public health concern, a new study shows that unsupervised children are most at risk for bites, that the culprits are usually family pets and if they bite once, they will bite again with the second attack often more brutal than the first.The study, the largest of its kind, was done by Vikram Durairaj, MD, of the University of Colorado School of Medicine, who found that dogs usually target a child's face and eyes and most often...

RESEARCH TRIANGLE PARK, N.C., Sept. 28 /PRNewswire/ -- Of the many threats to human health, rabies is not often considered a serious concern in the U.S. because of its relative rarity. Yet the rabies virus is virtually always fatal if preventive treatment is not administered before the onset of symptoms. To educate healthcare providers and the community at large about the imperative need for proper rabies post-exposure treatments, Talecris Biotherapeutics, Inc. is sponsoring a range of...

Four children died and hundreds of people are being treated for rabies after being attacked by vampire bats in Peru, according to various media reports published late last week.The attacks were confirmed by Health Ministry official Jose Bustamente."At this moment, we're facing an outbreak of wild rabies, produced by the bite of infected bats, in the Urakusa community, especially among the Awajun peoples," Bustamante told RTV on Saturday."We have identified 508 people bitten who...

DENVER, July 30 /PRNewswire/ -- Morris Animal Foundation (MAF), a nonprofit organization that promotes longer, healthier lives for animals through humane research, recently funded a study to determine how educated veterinarians and physicians are about dog bite prevention techniques. Only 21 percent of veterinarians and 5 percent of physicians reported that they had acquired most of their knowledge about dog bites from medical or veterinary school. Most interesting, the study found that the...

SAN FRANCISCO, July 1 /PRNewswire-USNewswire/ -- As Californians head outdoors to enjoy the summer sun they can be exposed to potential dangers as well. The California Poison Control System (CPCS) offers tips for staying safe and happy this season. CPCS (www.calpoison.org) is available at 1-800-222-1222, 24 hours a day, seven days a week for immediate expert help and information in case of exposure to summer hazards. "With school out and the sun shining Californians are heading outside,"...

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells. Results published in PNAS characterize new BiTE antibodies generated to target...

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity.BRAF mutations are found in about 8...